FMI
AXSM icon

F/M Investments’s Axsome Therapeutics AXSM Stock Holding History

F/M Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Buy
13,409
+141
+1% +$30.6K 0.17% 97
2026
Q1 		$2.24M Sell
13,268
-27,864
-68% -$4.81M 0.15% 98
2025
Q4 		$7.51M Buy
41,132
+1,637
+4% +$229K 0.29% 88
2025
Q3 		$4.8M Buy
39,495
+7,279
+23% +$820K 0.19% 132
2025
Q2 		$3.36M Buy
+32,216
New +$3.41M 0.12% 182

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

F/M Investments's AXSM Position: Q2 2026 in Review

F/M Investments increased its Axsome Therapeutics (AXSM) stake by 1.1% in Q2 2026, buying an estimated $30.6K and bringing the position to 13,409 shares worth $3.28M. The position accounts for 0.17% of the portfolio, ranked #97.

F/M Investments first reported a position in AXSM in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.51M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • F/M Investments held 13,409 shares of Axsome Therapeutics worth $3.28M as of Q2 2026.
  • F/M Investments bought 141 Axsome Therapeutics shares in Q2 2026, an estimated $30.6K.
  • Axsome Therapeutics made up 0.17% of F/M Investments's portfolio in Q2 2026, its #97 holding.
  • F/M Investments first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • F/M Investments's Axsome Therapeutics position peaked at $7.51M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on F/M Investments's 13F filing for Q2 2026, filed 5 Aug 2026.